W. Hans Meisen
Director, Translational Development Center @City of Hope
Signup · Get unlimited contacts
WORK HISTORY
Director, Translational Development Center @City of Hope
Los Angeles, CA, US
Lead early‑stage clinical development for first‑in‑human and Phase 1 oncology programs, guiding assets from late preclinical through protocol development, IND submission, clinical start‑up, and trial execution- Shape program‑level strategy for cell therapies, cancer vaccines, and oncolytic viruses incorporating science and innovation trends- Evaluate external technologies and late‑preclinical assets from biotech/pharma partners; provide scientific and clinical input to make decisions on IIT/external‑sponsor trial feasibility and alignment with institutional priorities- Integrate biomarkers, imaging, and correlative studies into development plans to inform early efficacy signals, MOA understanding, and data‑driven go/ no-go decision‑making- Collaborate closely with CMC and process development teams to optimize manufacturing, release testing, and regulatory strategy for early‑stage programs- Navigate regulatory strategy for FIH trials, contributing to IND packages, regulatory interactions, and risk‑mitigation planning- Manage program budgets and resource allocation for multiple clinical programs- Lead cross‑functional teams spanning Clinical Operations, Regulatory, Biostats, Safety, CMC, Quality, and Research to ensure coordinated execution and strategic clarity- Build and maintain partnerships with biotech/pharma companies, investigators, and KOLs to bring innovative platforms into the institution and expand the translational pipeline- Contribute to institutional strategy for cell therapy and emerging modalities- Author clinical protocols, INDs, investigator brochures, informed consents, statistical analysis plans, and other regulatory documents supporting early‑stage development.
EDUCATION
The Ohio State University
Doctor of Philosophy (PhD), Biomedical Sciences
University of Virginia
Bachelor of Science (BS), Biology/Biological Sciences, General
Georgetown University
Master of Science (MS), Biohazardous Agents and Emerging Diseases
ABOUT W. HANS MEISEN
Clinical development leader with over 12 years\' experience advancing oncology therapeutics from research to clinical trials. Proven in leading cross-functional clinical, research, regulatory, correlative/biomarker, and CMC teams to execute trials with both industry and academic partners. Experience leading IND development and submissions as well as trial startup and execution. Built key partnerships with investigators, key opinion leaders, and pharma partners to explore new therapies and technologies.
This profile is compiled from publicly available professional sources. Unifers is not affiliated with or endorsed by LinkedIn. Request removal of this profile.